Clinical Study

Nrg-Gy018- A Phase III Randomized, Placebo-Controlled Study Of Pembrolizumab (Mk-3475, Nsc #776864) In Addition To Paclitaxel And Carboplatin For Measurable Stage III Or Iva, Stage Ivb Or Recurrent Endometrial Cancerchemoradiation Plus Atezolizumab

Posted Date: Mar 6, 2020

  • Investigator: Amanda Jackson
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to evaluate the progression free survival of pembrolizumab in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer.


To Be Eligible: Measurable Stage Iii, Iva, Or Ivb, Or Recurrent (With Or Without Measurable Disease) Endometrial Cancer. Ecog 0-2, Normal Tsh Levels, No Hypersensitivities To Study Drugs Or Excipients, No Immunodeficiency, Any Active Or Uncontrolled Illness Or Infection That May Impact Study Results


Endometrial Cancer, Uterine Cancer

For More Information:

Uc Cancer Center